Great to see the impact of our @MassGenBrigham Heart and Vascular Institute clinical trial leaders at the @CVCTForum including a great session on AF outcomes in trials lead by our future Chief of Cardiology @CMAlbertEP
The Finnish-enriched SCN5A missense variant acted like a genetic proxy for cardiac Na channel blockade in a multi-cohort observational study with >1 million individuals. The variant can reduce the genetic liability for AFib conferred by common variants.https://t.co/0blz7W38Zb
She is widely recognized for her collaborative leadership style, dedicated mentorship, commitment to developing physician-scientists, advancing education, and ensuring the highest quality patient care.
Huge congrats to @AjufoEzim on her excellent YIA presentation #AHA2025 on effects of exercise in phenotype-negative cardiomyopathy variant carriers!
MVPA associated with lower CV outcomes with no signal for risk of CMP or VT
@MGHHeartHealth@broadinstitute@patrick_ellinor
🚨 New in @CircAHA : Maternal CVD and pregnancy-related CV complications are rising sharply over 2 decades across >56K pregnancies across @MassGenBrigham.
Pregnancy is a critical window for lifelong heart health!
🔗https://t.co/H6d6FvwRdr
@MGBResearchNews#CardioObstetrics
First Inova-MGB YIA in Women’s CVH is a wrap. Congratulations to all the young researchers and mentors! Looking forward to hosting next year in #NOVA@ISHVnews @MGHWomenHeart
Thrilled to announce that we are seeking a visionary leader to serve as our next Chief of Cardiology @MassGenBrigham. A unique opportunity to lead the integrated cardiology divisions at BWH & MGH (aka @BrighamWomens & @MassGeneralNews).
https://t.co/hUlf5g4v10
Our new chief will:
- Lead our team of 350+ physicians and 1,500+ staff throughout MGB
- Drive groundbreaking cardiovascular research with 150+ principal investigators
- Advance our exceptional training programs for future medical leaders